We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.16 | -1.85% | 8.49 | 80,227 | 16:35:29 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 8.20 | 8.78 | 8.50 | 8.22 | 8.32 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 13.93M | 1.29M | 0.0043 | 19.12 | 26.16M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:12:39 | O | 7,122 | 8.266 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/6/2025 | 07:00 | UK RNS | Futura Medical PLC Result of AGM |
| 02/6/2025 | 15:15 | UK RNS | Futura Medical PLC Block Listing Six Monthly Return |
| 27/5/2025 | 07:00 | UK RNS | Futura Medical PLC Notice of AGM and availability of Annual Report |
| 24/4/2025 | 07:00 | UK RNS | Futura Medical PLC Change of Broker |
| 15/4/2025 | 21:47 | ALNC |  EARNINGS AND TRADING: Everyman Media loss widens; Kooth back in profit |
| 15/4/2025 | 07:00 | UK RNS | Futura Medical PLC Results for the Year ended 31 December 2024 |
| 10/4/2025 | 13:30 | UK RNS | Futura Medical PLC Notice of Results and Investor Presentation |
| 31/3/2025 | 07:00 | UK RNS | Futura Medical PLC Board Appointment |
| 31/1/2025 | 11:39 | ALNC | After bumper 2024, Futura warns of lower 2025 sales on slow US uptake |
| 30/1/2025 | 07:00 | UK RNS | Futura Medical PLC FY24 Trading Update and FY25 Outlook |
Futura Medical (FUM) Share Charts1 Year Futura Medical Chart |
|
1 Month Futura Medical Chart |
Intraday Futura Medical Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/6/2025 | 12:32 | FUTURA a winner for 2015 | 22,047 |
| 07/10/2024 | 07:46 | fum value | 5 |
| 05/6/2024 | 19:50 | Berenberg upgrading Haleon | - |
| 30/5/2024 | 10:36 | FUM this ones bound to rise! | 94 |
| 02/7/2023 | 10:15 | Quiet on here | 34 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:12:40 | 8.27 | 7,122 | 588.70 | O |
| 12:55:20 | 8.27 | 1,828 | 151.10 | O |
| 12:53:33 | 8.60 | 8,000 | 688.16 | O |
| 11:09:28 | 8.60 | 851 | 73.20 | O |
| 10:22:26 | 8.22 | 2,829 | 232.54 | AT |
| Top Posts |
|---|
Posted at 23/6/2025 09:20 by Futura Medical Daily Update Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 8.65p.Futura Medical currently has 302,403,003 shares in issue. The market capitalisation of Futura Medical is £24,857,527. Futura Medical has a price to earnings ratio (PE ratio) of 19.12. This morning FUM shares opened at 8.32p |
Posted at 23/6/2025 12:32 by onedayrodders "It's not some super stiffening or enlarging agent sold to enhance male prowess and turn you into a porno stud!!"That's right Glavey.. in fact the paying public have confirmed it's actually not ANYTHING but a useless irrelevant gel with fake promises. I'll leave the share price to do the talking TTFN |
Posted at 15/4/2025 10:01 by bandflex 2024 full year UK and Euro revenue £47788702024 H1 UK and Euro revenue £2759280 So H2 revenue fell to £ 2019590 even though it was released in more euro countries. 2024 rest of world full year revenue £1,312,198 2024 H1 rest of world revenue £ 1,014,830 So 2024 H2 rest of world revenue cratered to £ 297368 US launched in 2024 H2 so no comparison for sales revenue only milestone payments. Sales have clearly fallen towards the end of 2024 and have gotten worse in all markets in 2025, but FUM will hide the figures until the 2025 H1 results sometime in September. So get ready for 5 months of BS from FUM before reality hits. |
Posted at 15/4/2025 08:25 by kinwah MDI well done reading through to the end. The provision you picked up is due to FUM not calling off enough manufactured stock from its supplier due to poor demand. The extent of this contractual commitment is unknown but is a big worry. No wonder the auditors were shuffling in their seats. |
Posted at 15/4/2025 08:13 by kinwah The clues are there. The bulk of the sales come from 'retailer sell-in', i.e. stocking up on launch. Hence the interest in Eroxon Intense which would give FUM another chance of launch sales. The big non-mention in these results is repeat sales to consumers and we know that is because they are so poor. Most men who try it are dissatisfied with the outcome. FUM say targeting those men for whom it works is proving difficult especially as the 'wrong men' like older blokes try it out of interest only to be disappointed. Sadly I think FUM has to put itself up for sale before it runs out of cash. |
Posted at 19/3/2025 09:22 by glavey << LOST PET >>Missing since January 19th, 2025. If found, please return to ADVFN FUM board. |
Posted at 07/2/2025 12:27 by sphere25 No sign of rampers MDI....because the share price is......having a hard time (Couldn't help it) (Really couldn't) Here all week....with no coat |
Posted at 08/11/2024 07:53 by m_night10 POLX Polarean Imaging about to break out above 2p soon. Mcap only $25mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.65p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 04/11/2024 07:45 by ajmace Two new products should provide a fillip to the FUM share price |
Posted at 04/9/2024 18:25 by mdi Glavey and apparently sales are still flying? Again as you say or ‘so BB chatter would have us believe’. But an undisputed fact is FY 2023 results clearly showed Eroxon sales declined in the UK and Belgium in H2 versus H1. Even though everyone kept saying it was the ‘top 5 best selling product’ on Boots, Amazon etc etc. Just like ‘BB chatter’ said was happening at one time with Epic sales supposedly flying on Amazon. But it definitely doesn’t have any sales now and no sign of it anywhere on any best selling lists on Amazon or ever coming back.And oddly enough the share price has again even closed lower today then when similar ‘BB chatter on how well Eroxon was supposedly doing according to some crude online checks which seems to be posted regularly. Seems its be proven now beyond a doubt by the actual 2023 results relying on such ‘BB chatter’ on supposed best seller claims is yet another thing that is definitely ‘pointlessReyeofthetiger - 08 Jan 2024 - 08:30:14 - 20045 of 21589 Eroxon is a game changer product that rivals Viagra without having to pop a pill. Results are due in the weeks ahead and you only need to visit the Boots website to see that the product is flying off the shelves. Take a look at the online store and one can see It has recently been promoted and marketed as a top 5 best selling product for Boots! I think investors are finally going to see the pot of gold they have been waiting for.....(waiting for years might i add). Review the historic highs and we were significantly higher during clinical trials. Eroxon is now a fully commercial product and the upside potential is vast especially from these lows. Mark this message because I think we are going to see a strong rise in the weeks ahead. I mean 3-5x current share price |
Posted at 04/5/2024 16:53 by mdi How much has the Futura market cap declined now since June of last year? I read that the major shareholders average price is still well below even the current share price. So even even if the share price declines further they will still be in profit. So will Directors on many of their 7p and 15p share options if the share price even falls another 40% to the low 20’s. That would still be a Market Cap of nearly £70mHard to tell which is falling faster now. Eroxon sales after the hype or the Futura market cap after the hype. But the fact remains that the £1.7m revenue in April/May was followed by only £1.4m in the following 6 months. New market launches being hyped and staggered may well help short term to prop up the obvious declining sales. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
